Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Uplizna
Pharma
Amgen's products from buyout of Horizon continue to struggle
While Amgen’s legacy products are thriving, those gained from the company’s 2023 buyout of Horizon are struggling, especially blockbuster Tepezza.
Kevin Dunleavy
May 2, 2025 8:18am
Amgen's Uplizna posts strong results in myasthenia gravis trial
Sep 25, 2024 11:37am
Amgen's Uplizna proves its worth in another rare disease
Jun 5, 2024 11:00am
